Aktuella utlysningar, vecka 20, 2017
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anlag
Projektanslag för forskning om multipel skleros - Hildegard Machschefes donation, Svenska Läkaresällskapet
Svenska Läkaresällskapet inbjuder ansökningar ur Hildegard Machschefes donation till forskning för att bota sjukdomen multipel skleros. Detta stöder forskningsprojekt inom multipel skleros. Projektet ska fokusera på uppföljning av behandling av multipel skleros baserad på autolog blodstamcellstransplantation. Projektets uppföljningsdel skall inkludera användning av olika typer av biomarkörer och relevanta patientnära utfallsmått. Ansökningar som innehåller en nationell ansats och projekt som involverar forskargrupper vid flera universitet eller universitetssjukhus i Sverige prioriteras. Svenska Läkaresällskapet utlyser ett eller högst två projektbidrag med fokus på uppföljning av behandling av multipel skleros baserad på autolog blodstamcellstransplantation. Totalt finns c:a 3,5 mkr disponibelt för att utnyttja under som längst 4 år. Medlemskap i Svenska Läkaresällskapet krävs.
Closing date: 20 June 2017
Biotechnology-based synthesis and production grants – Novo Nordisk Foundation
Applications are invited for project grants within biotechnology-based synthesis and production research. These grants support fundamental and applied research projects aimed at generating products in improved and more sustainable ways. Projects must involve a clear element of biotechnology, and may in addition utilize any other scientific and engineering discipline relevant to achieve the objectives. Projects must contain a laboratory component. Applications are welcomed from faculty members and researchers with an independent research programme at a university or other non-profit research institution in Denmark, Finland, Iceland, Norway or Sweden.
Closing date: 21 June 2017
Kongresstiftelsen – Svenska Läkaresällskapet
Svenska Läkaresällskapet inbjuder ansökningar om bidrag ur kongresstiftelsen. Detta stöder organiserande av internationella konferenser genom förfinansiering.
Closing date: 1 September 2017
Forskningsanslag – Forska Utan Djurförsök
Forska Utan Djurförsöks uppgift är att se till att djurförsök ersätts med nya, bättre metoder. Genom forskningsanslag bidrar de till medicinsk forskning och förbättrad riskbedömning av kemikalier, läkemedel och andra produkter, samtidigt som djurförsök ersätts. Forska Utan Djurförsök stödjer nästan enbart forskningsprojekt som utförs i Sverige eller som har svenska deltagare. Forskningsprojekten kan syfta till att ersätta djurförsök som förekommer antingen nationellt eller internationellt.
Closing date: 1 September 2017
Nordic research projects in medicine 2018 – The Olav Thon Foundation
The Olav Thon support research the fields of mathematics, natural sciences and medicine. For 2018 the Foundation will reserve NOK 20 million for grants to Nordic research collaboration in the field of medicine. Only researchers associated with universities or academic institutions in the Nordic countries are eligible for support. Previous collaboration will be regarded as an advantage and should be documented (by co-publications or similar). The collaboration must include specific research groups in at least two Nordic countries and be led by personnel holding professorships or equivalent permanent academic positions.
Closing date: 15 September 2017
Stipendier för masters-, doktorand- och postdoktorala studier i USA och Kanada – Sverige-Amerika Stiftelsen
Sverige-Amerika Stiftelsen möjliggör akademisk utbildning, forskning och praktik i USA och Kanada för talangfulla och motiverade studenter. När de återvänder till Sverige har de med sig spjutspetskompetens, internationella erfarenheter och kontakter av stort värde för svenskt näringsliv, samhällsliv och forskning.
Closing date: 15 September 2017
Léopold Griffuel awards - ARC Foundation for Cancer Research
These recognise researchers whose work has led to a major breakthrough in fundamental or applied research in oncology. Each prize is worth a total of €150,000, including €25,000 remitted to the recipients during the award ceremony.
Closing date: 30 Jun 2017
Ferring innovation grants - Ferring Pharmaceuticals
These support exploratory, discovery and preclinical research into novel extracellular drug targets that are addressable with peptides or proteins in the fields of reproductive health, urology, gastroenterology, hepatology and endocrinology. Grants are worth between USD 50,000 and USD 100,000 over one year.
Closing date: 12 Jun 2017
Fellowship programme on guideline methodology - European Respiratory Society
This provides training and placements for researchers to gain theoretical and practical skills for developing high quality guidelines. The fellowship will last six months in total and must be carried out in a full time basis. Funding covers living costs and travel between home and host institutions.
Closing date: 3 Jul 2017
Research grants - Froebel Trust
These support research projects that address Froebelian priority themes, such as disadvantage and valuing diversity, childhood under stress, and adult engagement with young children. The total budget is worth £150,000.
Closing date: 1 Jul 2017
Federal Funding agencies
Idea Development Award, Bone Marrow Failure Research Programme (BMFRP) – Department of Defense, US
This supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the BMFRP vision of understanding and curing bone marrow failure diseases. The grant is worth up to USD 315,000 for a maximum period of two years.
Closing dates: Pre-applications due by 5pm Eastern Time (ET), 13 July 2017; full applications due by 11.59pm ET, 5 October 2017.
Opportunity Number: W81XWH-17-BMFRP-IDA
Ovarian Cancer Research Funding Opportunities - Department of Defense, US
This supports the exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. Clinical trials are not supported by this award. Grants are worth up to USD 250,000 each for up to two years.
Closing dates: Pre-proposals due by 5pm Eastern Time (ET), 14 June 2017; full applications due by 11.59pm ET, 24 August 2017.
Opportunity Number: W81XWH-17-OCRP-PA
Clinical Development Award
This supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment or quality of life. The goal is to accelerate the clinical introduction of medical products and technologies that target ovarian cancer biology. Near-term clinical impact is expected. Grants are worth up to USD 600,000 for up to three years. An additional USD 200,000 is available to support a nested early-career investigator.
Closing dates: Pre-applications due by 5pm Eastern time, 21 June 2017; full applications due by 11.59pm Eastern time, 6 September 2017.
Opportunity Number: W81XWH-17-OCRP-CDA
Investigator-initiated Research Award
This supports high-impact research that has the potential to make an important contribution to ovarian cancer or patient or survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. Grants are worth up to USD 450,000 each in direct costs over a maximum period of three years.
Closing dates: Pre-applications due by 5pm ET, 21 June 2017; full applications due by 11.59pm ET, 6 September 2017
Opportunity Number: W81XWH-17-OCRP-IIRA
Ovarian cancer academy – early career investigator award
This enables early career investigators to pursue an ovarian cancer project that may be basic, translational or clinical research under the guidance of a designated mentor. Clinical trials are not allowed. The award is worth up to USD 725,000.
Closing dates: Pre-applications due by 5pm ET, 21 June 2017; applications due by 11.59pm ET, 6 September 2017. This call is repeated once a year.
Opportunity Number: W81XWH-17-OCRP-OCA
Breast Cancer Research Funding Opportunities - Department of Defense, US
Era of Hope Scholar Awards
These support individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. PIs must be independent investigators within six years of their last training position. Experience in breast cancer research is not required; however, applicants must focus on breast cancer. Each award is worth up to USD 2.5m in direct costs for up to four years.
Closing dates: Letter of Intent (LOI) due 8 June, 2017; full applications due 15 June 2017.
Opportunity Number: W81XWH-17-BCRP-EOHS
The intent of the Breakthrough Awards is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement. Partnering PI Option allows two Principal Investigators (PIs) to collaborate on a single application.
* Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required. Clinical trials not allowed. Maximum funding of $375,000 for direct costs (plus indirect costs); maximum period of performance is 3 years. Partnering PI option: Maximum funding of $600,000 for direct costs (plus indirect costs); maximum period of performance is 3 years.
* Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation. Clinical trials not allowed. Maximum funding of $750,000 for direct costs (plus indirect costs); maximum period of performance is 3 years. Partnering PI Option: Maximum funding of $1 million (M) for direct costs (plus indirect costs); maximum period of performance is 3 years
* Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply. Maximum funding of $2.5M in direct costs (plus indirect costs); maximum period of performance is 4 years. Partnering PI Option: Maximum funding of $4M for direct costs (plus indirect costs); maximum period of performance is 4 years
* Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. Human clinical testing is required. PIs are expected to have experience in successfully leading large-scale projects. Maximum funding of $10M for direct costs (plus indirect costs); maximum period of performance is 4 years (same for Partnering Option)
Closing dates: Funding Levels 1&2: Letter of Intent (LOI) due 8 June, 2017; full applications due June 15, 2017. Opportunity Number: W81XWH-17-BCRP-BREAKTHROUGH-FL12. Funding Levels 3&4: Pre-applications due June 9, 2017; full applications due 31 August, 2017. Opportunity Number: W81XWH-17-BCRP-BREAKTHROUGH-FL34
Distinguished Investigator Award
Assistant Professor or above (or equivalent) and more than 6 years beyond the PI's last training position as of the application submission deadline. Seeks new paradigms in breast cancer research by supporting investigators who are established and recognized leaders with a renowned reputation in their field and who propose a fundamental shift from his/her track record of research. Maximum funding of $3M for direct costs (plus indirect costs); maximum period of performance is 4 years.
Closing dates: Pre-application due June 9, 2017. Full application due August 31, 2017.
Opportunity Number: W81XWH-17-BCRP-DIA
Breakthrough Fellowship Award
This supports recent doctoral or medical graduates in pursuit of breast cancer research during their postdoctoral fellowship and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research. Awards are worth up to USD 300,000 to cover direct costs, for a duration of up to three years.
Closing dates: Pre-application due June 8, 2017; full application due June 15, 2017
Opportunity Number: W81XWH-17-BCRP-BREAKTHROUGH-FELLOWSHIP
This supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer. The award is worth up to USD 5 million in direct costs over a maximum period of four years.
Closing dates: Pre-applications due June 9, 2017. Full application due August 31, 2017.
Opportunity Number: W81XWH-17-BCRP-INNOV
Amyotrophic lateral sclerosis research programme - Department of Defense, US
Therapeutic Development Award
This supports innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. The award supports a wide range of development activities ranging from validation of therapeutic leads to US Food and Drug Administration investigational new drug submission. Applications supported by this award must begin with lead compounds in hand. A total budget of USD 3.2 million is available for two awards.
Closing dates: Pre-applications due June 9, 2017. Full application due August 31, 2017.
Opportunity Number: W81XWH-17- ALSRP-TDA
Therapeutic Idea Award
This promotes new ideas aimed at drug or treatment discovery that are still in the early stages of development. Development, modification and validation of preclinical model systems or the application of high-throughput screens to define or assess lead compounds for ALS treatment are of interest. Awards are worth up to USD 500,000 each over two years.
Closing dates: Pre-applications due June 9, 2017. Full applications due August 31, 2017.
Opportunity Number: W81XWH-17-ALSRP-TIA
Research grants (extended deadline) - National Multiple Sclerosis Society, US
These support fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care and rehabilitation. Grants are awarded for one to five years and may cover salaries up to USD 199,700 per annum, postdoctoral training support up to USD 56,376 annually, insurance premiums and patient costs.
Closing dates: pre-applications due July 26, 2017; full applications due August 2, 2017, 5:00 pm EST
Research grants - Lung Cancer Research Foundation, US
These support innovative research projects focused on the prevention, diagnosis, treatment and cure of lung cancer. Projects areas include basic science, translational science, clinical research, supportive care and quality of care or outcomes. Grants are worth up to USD 150,000 over two years.
Closing dates: Applications due July 1, 2017.